The selective blocker of SLC6A14, α-methyl-dl-tryptophan (α-MT), when used in vitro on ER-positive MCF7 breast cancer cells, can induce amino acid deprivation, inhibit mTOR, and activate autophagy. Here, MTOR is linked to breast carcinoma.